You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

    SBC: NUVOX PHARMA, L.L.C.            Topic: 102

    Glioblastoma multiforme (GBM) is a malignant primary brain tumor affecting about 12,000 new cases per year in the U.S. Average survival is only about 14-15 months. Radiation (RT) is most commonly administered as 30 fractions of 2 Gray each over 6-weeks with concomitant temozolomide (TMZ). GBM tumors are hypoxic. The primary mechanism of RT is creation of singlet oxygen; hypoxia within GBM adversel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. An Integrated Microarray Printing and Detection System

    SBC: BIOSENSING INSTRUMENT INC            Topic: 400

    DESCRIPTIONprovided by applicantMicroarray technology has dramatically advanced the study of protein interactions leading to discovery and validation of new biomarkers and therapeutic drugsTypicallyprotein microarrays are pre spotted with target molecules in one device and then tested with probe molecules using another deviceDuring each testing cyclethe entire microarray becomes exposed to the pro ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Genome Mining the Full Diversity of the Actinomycete Biosynthetic Universe for Neomorph Antibiotic Discovery

    SBC: WARP DRIVE BIO, LLC            Topic: NIAID

    ABSTRACT To combat multidrug resistant bacterial infections novel classes of antibiotics with new mechanisms of action are desperately required Genome mining for novel natural products is quickly replacing traditional approaches to antibiotic discovery Warp Drive Bio has sequenced over actinomycete strain genomes from diverse sources worldwide and our proprietary genomic database conta ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Selection of a device for intranasal administration of a mucosal vaccine for HSV

    SBC: Biomedical Research Models, Inc.            Topic: R

    Globally an estimated of the human population is infected with HSV including andgt of the U S adult population Genital herpes is associated with an increased risk of HIV acquisition and transmission of HSV infection can cause neonatal herpes with high infant mortality HSV infection in the adult population has increased substantially in the past two decades despite the availabil ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Harnessing Genomic Information to Engineer Combinatorial Biosynthesis of a Large Polyketide Natural Products Library

    SBC: WARP DRIVE BIO, LLC            Topic: NIAID

    Abstract Natural products have outstanding pharmaceutical pedigree approximately of FDA approved small molecule drugs are derived from plant bacterial or fungal sources To discover new natural products Warp Drive Bio has assembled an enormous proprietary and searchable database of microbial genomes and biosynthetic gene clusters To date our database comprises genomes sequenced ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Screening for rAAV transduction enhancers

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    ABSTRACT Recombinant adeno associated virusrAAVis a promising gene delivery vector for therapeutic and vaccine applicationsbut its low transduction efficacy currently limits its utilityThe primary reasons for low transduction efficacy are as followsiinefficient trafficking of the rAAV genome to the nucleusiiinefficient host cell mediated synthesis of double stranded DNA from the single stranded ge ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Enhancing cytarabine efficacy in leukemia through CDK inhibition

    SBC: SENEX BIOTECHNOLOGY, INC.            Topic: 102

    Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeutic agent used in AML AraC containing chemotherapeutic regimens induce complete remission in of newly diagnosed AML patients but a substantial minority of leukemias is intrinsically resistant t ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Optical Dosimeter guided Photodynamic Therapy

    SBC: PHYSICAL SCIENCES INC.            Topic: 102

    Photodynamic Therapy PDT is a promising modality for cancer treatment Oxygen molecules in the metastable singlet delta state O are believed to be the species that destroys cancerous cells during PDT Despite the benefit of targeted PDT that kills tumors selectively with minimum effect on surrounding healthy tissues at the present time it is difficult if not impossible to predict the res ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Improving delivery of paclitaxel to ovarian cancer via expansile nanoparticles

    SBC: IONIC PHARMACEUTICALS, LLC            Topic: 102

    ABSTRACT A primary challenge in ovarian cancer is preventing tumor recurrence in patients following a resection debulking procedure year survival rate andlt Intraperitoneal IP administration of chemotherapy most notably paclitaxel can improve patient outcomes and prevent local tumor recurrence the principal deterrent to long term survival However despite these modest improvement ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Immuno-PCR for Detection of Toxins in Medicinal Cannabis

    SBC: COURTAGEN LIFE SCIENCES, INC.            Topic: NIDA

    Abstract The overall goal of this project is to develop an optimized assay design and development process to permit the rapid implementation of sensitive bead based immuno PCR assays for the detection of the major bacterial and fungal toxins that are produced by common contaminants of medicinal cannabis The assay process will be developed and validated in Phase I focusing on one important small ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government